The Claim

In patients following myocardial infarction, the one-year incidence of major adverse cardiovascular events was 1.79 per 100 patient-years among those receiving early ezetimibe, 2.58 among those receiving late ezetimibe, and 4.03 among those not receiving ezetimibe.

Source: Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
59score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

People who had a heart attack and started taking a cholesterol drug called ezetimibe early had fewer heart problems over the next year compared to those who started later or didn’t take it at all.

See the scientific wording

One-year incidence of major adverse cardiovascular events was 1.79 per 100 patient-years in patients receiving early ezetimibe, 2.58 in those receiving late ezetimibe, and 4.03 in those not receiving ezetimibe after myocardial infarction.

What the research says

1 study

  1. Study: Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry.

    The study looked at when heart attack patients started taking ezetimibe and found that those who started early had fewer heart problems over time, just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.